Stage (next event)
Catalyst Info & Data Links
TITLE: TGFTX1 for Psoriasis or Respiratory Conditions (Pre-clinical)
WHAT IS THE NEXT CATALYST EVENT?
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
Helleboid, S., Haug, C., Lamottke, K., Zhou, Y., Wei, J., Daix, S., ... & Walczak, R. (2014). The identification of naturally occurring neoruscogenin as a bioavailable, potent, and high-affinity agonist of the nuclear receptor RORα (NR1F1). Journal of biomolecular screening, 19(3), 399-406.
MECHANISM OF ACTION
Our TGFTX1 preclinical program is focused on the discovery and development of innovative drug candidates targeting RORγt, a key nuclear receptor that directs IL-17 mediated immunity. In particular, we focus on treating psoriasis or respiratory conditions such as neutrophilic asthma, chronic obstructive pulmonary disease, or COPD, and the asthma-COPD overlap syndrome (ACOS).
Updated by MV
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post